SCHEMBL10072192

SCHEMBL10072192

Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3cccc(OC(F)F)c3)ccc1C)c(=O)n2C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.52
MEN1 O00255 4/20 0.45
MAPT P10636 4/20 0.45
KMT2A Q03164 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
POLB P06746 3/20 0.45
NPSR1 Q6W5P4 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
HTT P42858 1/20 0.45
ALDH1A1 P00352 1/20 0.45
PKM P14618 1/20 0.45
GAA P10253 1/20 0.44
BRAF P15056 5/20 0.44
RAF1 P04049 4/20 0.44
LMNA P02545 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043761 0.93 SYK (0.51) SYKMEN1MAPTKMT2ASMN1; SMN2
SCHEMBL10043749 0.91 SYK (0.55) SYKBRAFRAF1ABL1
SCHEMBL10043704 0.91 BRPF1 (0.53) SYKMEN1MAPTKMT2ASMN1; SMN2
SCHEMBL10043662 0.89 SYK (0.54) SYKMEN1MAPTKMT2ASMN1; SMN2
SCHEMBL10043677 0.89 NPC1 (0.52) SYKMEN1MAPTKMT2ASMN1; SMN2
SCHEMBL10072186 0.87 SYK (0.55) SYKMEN1MAPTKMT2ARAB9A
SCHEMBL10043863 0.86 SYK (0.46) SYKMEN1MAPTKMT2ASMN1; SMN2
SCHEMBL10043699 0.86 SYK (0.57) SYKMEN1MAPTKMT2ASMN1; SMN2
SCHEMBL10072188 0.85 SYK (0.53) SYKMAPTNPC1BRAFABL1
SCHEMBL10043703 0.85 SYK (0.51) SYKBRAFRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885MEN1 4240/4885MAPT 2514/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885MEN1 4240/4885MAPT 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.